

Health Intelligence

Revolutionizing Healthcare: The Future of Wearables, Al, and Remote Patient Monitoring

Enabling Healthier Futures

February 14th, 2024





Forward Looking Statement

This presentation may contain forward-looking statements that involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of AI/ML Innovations Inc., or industry results to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Forward-looking statements, which may include but are not limited to, projections regarding future revenues, earnings, strategies, and prospects, are based on numerous assumptions and factors that are inherently uncertain. These assumptions and factors include, but are not limited to, the availability of financing for AI/ML Innovations Inc's projects, changes in commodity prices, changes in demand for and supply of commodities, economic and competitive market conditions, and the regulatory environment. Investors are cautioned not to put undue reliance on forward-looking statements. By their nature, forward-looking statements involve numerous assumptions, inherent risks, and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections, and various future events will not occur. AI/ML Innovations Inc., undertakes no obligation to update publicly or otherwise revise any forward-looking statements, whether as a result of new information, future events, or other such factors that affect this information, except as required by law.



Enabling Healthier Futures

TOWN HALL AGENDA

- What we Do
- The Next 90 Days
- Milestones & Updates
- Questions & Answers





The AI/ML Biometric Journey

Capture

Smart Sensor Wearables Capture biometric signals or pulses through our "Pulse Whisperer"

API's, Connectors, SDK For Time-Series Data

Collection

Analyze

Analyze using our <u>proprietary</u> and <u>patented</u>

Neural Networks, Machine Learning, and Artificial
Intelligence services to create an accurate


"Biometric Information Pulse"

Action

Action with Predictive Analytics for personalized insights through our Biometrics Platform to "inform" the right Adaptive Care Pathways and advanced Remote Patient Monitoring



2023 Innovation Grand Prize at the prestigious L'Encéphale Medical Congress in Paris











Non-invasive AI/ML Blood Pressure





The First 100 Days: Milestones Q4, CY 2023

One: Book \$1.0MM in orders for 2024

- Health Gauge Inc. (95.2% owned by AIML)
 - In North America, renews approximately \$300K CDN
 - Professional Services & License Agreement of the Health Gauge
 Platform and Neural Net
- Tech2Heal (up to 22% ownership rights, 12.44% currently owned by AIML) & AI Rx Inc. (70% owned by AIML, 30% owned by Tech2Heal)
 - o In Europe, books approximately € 525K, \$750K CDN
 - EssilorLuxottica AR Eyewear Consortium, University Hospital of Nice Clinical Trials, Licensing and Professional Services deals in the UK, France and Nigeria.

Two: Prepare for FDA Submission of Neural Net and Care Pathway

- Health Gauge completes pre-trial training of the BPM NN
- Tech 2 Heal completes pre-trial validation for the **Care Pathway Studio**

Three: Raise \$1.0MM in new capital

Successfully closed \$750K in December





Sales are Starting

From Pitch to Purchase

Traction in the First 100 Days:

 Al and Remote Patient Monitoring for Blood Pressure Management

• Al Licensing for Patented Neural Net

Clinical Trial Management Systems

University Hospital of Nice Aging Well
 Clinical Study - 2 Trials Underway

 Europe's Largest Study for the Prevention of Loss of Autonomy in the Elderly

 Involves 30,000 patients & 10 research Laboratories

5 Year Studies







CLINICAL TRIAL HIGHLIGHTS

Personalized program for preventing loss of autonomy in the elderly: Key Metrics - Accessibility, Empowerment, and Environmental Adaptations



The CHU is launching the biggest decentralized clinical trial in order to prevent loss of autonomy in the elderly.

With a goal to develop a program to **prevent loss of autonomy in elderly people** who are remote from the healthcare system



The cohorts will be composed of **30,000 citizens** from the city of Nice and its surroundings aged between **50 and 70 years.**

Testimony: "Our stakes are immense and we are pleased to take the ride with Tech2heal for the next five years. **The platform is the backbone of our project**."

Olivier Guerin, Professor in Geriatric



My Health Friend

Funded by a European Commission Fund


Multi-language Health App for Cross-Border Populations (French, Italian, English) Personalized Digital Rehabilitation to Prevent Chronic Diseases, Reduce Socio-Health
Impact.

Objective 1 - Setup and Data Collection

- Target Study: General population in transalpine regions, application free to use
- Inclusion Period: 18 months, involving 1000-1500 individuals

Objective 2 - Assessing Impact

- Target: 50 patients with chronic neurological diseases aged
 14 to 80 (territory residents)
- Supervised use by healthcare professionals over 6 months
- Measure satisfaction levels and well-being/quality of life impact








Prescription for Growth:

Investing in the Clinical Trials Boom



The global **clinical trial management system** market size was estimated at **USD 1.6 billion in 2022** and it is expected to reach around **USD 5.22 billion by 2032**, poised to grow at a compound annual growth rate **(CAGR) of 12.6%** during the forecast period 2023 to 2032.



The Next 90 Days: Milestones Q1, CY 2024

One: Build Funnel, Create Pipeline

- <u>Jan 15th</u> Launch of the **Health Gauge Biometrics** website
 - o Aligned to Product / Market Fit with SEO/SEM for Lead Gen
- Secure Pilot Programs and New Accounts

Two: Build Products

- Jan 31st Launch of v1.0 of The Pulse Whisperer for Biometric Raw Signal Data
 - Capture unlimited time-series biometric data from our smart sensors for Research in Life Sciences
- <u>February 29th</u> Launch vl.0 of **Follow Your Heart** Measure, Monitor and assist with the Management of your Blood Pressure
 - Our non invasive Blood Pressure Smart Sensor Watch using our Patented
 Neural Network and sold through pharmacy retail & other partners
- March 31st, Introducing Version 2.0 of the Health Gauge Biometrics Platform for Health Sciences. Biometric Magic with Capture, Analyze and Action
 - This will be our primary platform going forward.

Three: Build More Value


- Setup Al Rx Inc., Operating Co. with transfer & setup of Alakin Health Platform
- Complete Neural Net Training, Prepare for FDA Submission
- Secure Grants & Research Programs and additional non-dilutive funding
- Establish a world-class Science & Product Advisory Council

Biometrics Unleashed

Welcome to Health Tech 2.0
The Era of Health Intelligence

At the dawn of 2024, advancements in Artificial Intelligence (Al), Predictive Analytics (PA), Large Language Models (LLM) and Transformers (GPT) have reset everything to a new normal.

Scroll to Dream





Follow Your Heart

Non Invasive Blood Pressure Measuremer 1 & Monitoring





Non-Invasive Blood Pressure Product

Heart Disease Impact



100 MILLION

PEOPLE AFFECTED IN NORTH AMERICA



1.5 BILLION

PEOPLE AFFECTED WORLDWIDE



400,000

RELATED DEATHS ANNUALLY IN USA



\$50 BILLION / YR \$

COST TO THE HEALTH SYSTEM

Unit Price \$249.99


Fact - Blood pressure measurement

is a **key diagnostic and preventive**

tool in the context of heart disease



Units	Revenue
50,000	\$12,499,500
100,000	\$24,999,000
250,000	\$62,497,500
500,000	\$124,995,000
	50,000 100,000 250,000



Neural Nets: Training & FDA

Why are we doing all this?

- Biometric Smart Sensors need Neural Nets to convert Signals & Pulses to precise measurements.
 - Transforming millions of inputs into actionable insights through our innovative biometric InfoPulse. (more on this in our Next 100 Days)
- Advance our unique Value Proposition
 - Capture, Analyze & Action Biometric Measurements.

Who is leading the effort?

- Bruce Matichuk and his NN Dev team
- Randy Duguay and his team are running the NN Training
 Program this will be "Always On"
 - Please contact if you want to participate.

When will our NN be ready for FDA submission?

- Continuous training data will improve the accuracy of the neural network over time - "Always On"
- FDA Submission begins in Q1, 2024

Systolic Predictions vs Ground Truths

HG NN MARD Graph

Jan 10, 2024

- Juan Diego, Arsham Sarshogh

Current Data Pairs:

Total (over all time) data pairs = 12,960

From Nov 1, 2023


Total = 2506 pairs

NN pairs = 1861

IEEE 1708 / BHS GRADE A

HG NN

<u>n</u>		
≤ 5 mmHg	65% of data	51.0%
≤ 10 mmHg	85% of data	81.0%
≤ 15 mmHg	95% of data	92.0%



^{*} mmHG - Millimeters of Mercury

Diastolic Predictions vs Ground Truths

HG NN MARD Graph


Jan 10, 2024

- Juan Diego, Arsham Sarshogh

IEEE 1708 / BHS

GRADE A HG NN

≤ 5 mmHg	65% of data	71.0%
≤ 10 mmHg	85% of data	92.0%
≤ 15 mmHg	95% of data	98.0%



^{*} mmHG - Millimeters of Mercury

HEALTH GAUGE REGULATORY: Current NN Solution: Version 1.0 Model

... as of February 12, 2024

HG SYSTOLIC Blood Pressure

DIASTOLIC Blood Pressure

DATE	SYS (ST-Dev) mmHg	MEAN AVG Deviation (MAD)
Dec 6, 2023	9.98	9.19
Dec 9, 2023	9.27	9.10
Dec 12, 2023	9.11	8.73
Dec 14, 2023	9.02	8.59
Jan 02, 2024	6.99	7.24
Jan 10, 2024	5.98	6.73
Feb 01, 2024	5.31	6.36
Feb 12, 2024	5.28	<mark>6.24</mark>

DIA (ST-Dev) mmHg	MEAN AVG Deviation (MAD)
10.68	7.46
9.96	7.92
10.22	7.85
9.71	7.63
4.56	4.99
<mark>4.30</mark>	<mark>4.47</mark>
-	-

Note: The ST-DEV numbers and MAD numbers are getting lower.

This indicates the Neural Network is improving its ability to predict.

IEEE 1708 / BHS - DIASTOLIC GRADE A HG NN

≤ 5 mmHg	65% of data	<mark>45.1%</mark>	<mark>56.2%</mark>	<mark>62.7%</mark>	71.0%
≤ 10 mmHg	85% of data	<mark>74.5%</mark>	<mark>81.6%</mark>	86.5%	92.0%
≤ 15 mmHg	95% of data	<mark>89.4%</mark>	93.2%	95.2%	98.0%

IEEE 1708 / BHS - SYSTOLIC

GRADE A HG NN

≤ 5 mmHg	65% of data	43.7%	51.5%	49.1%	51.0%	49.0%	50%
≤ 10 mmHg	85% of data	<mark>69.6%</mark>	77.2%	75.6%	81.0%	80.0%	80.96%
≤ 15 mmHg	95% of data	80.6%	88.2%	87.7%	92.0%	93.0%	93.38%

Dec. 14. 2023 Dec. 18. 2023 120. 2024 120. 202

Dec 14, 2023 Dec 18, 2023 Jan 2, 2024 Jan 10, 2024

Restricting SBP between: 110-150mmHG

54.71%
84.76%
95.67%

Feb 12, 202A



Health Gauge Biometrics Platform for Life Sciences

Unleash your Quantified Self

Improve your health through an incremental and datainformed approach.

Learn more



Home Pro

Products ~

Solutions

Learn About Us

Log in

Support



Biometric Magic

Prioritize Your Well-being: Where Continuous Monitoring, Precision, Privacy, and Health take Center Stage



Questions & Answers

Revolutionizing Healthcare: The Future of Wearables, Al, and Remote Patient Monitoring

Enabling Healthier Futures

